| Virological assessment of hospitalized patients with COVID-2019 R Wölfel, VM Corman, W Guggemos, M Seilmaier, S Zange, MA Müller, ... Nature 581 (7809), 465-469, 2020 | 7766 | 2020 |
| Transmission of 2019-nCoV infection from an asymptomatic contact in Germany C Rothe, M Schunk, P Sothmann, G Bretzel, G Froeschl, C Wallrauch, ... New England journal of medicine 382 (10), 970-971, 2020 | 5578 | 2020 |
| Global trends in molecular epidemiology of HIV-1 during 2000–2007 J Hemelaar, E Gouws, PD Ghys, S Osmanov Aids 25 (5), 679-689, 2011 | 845 | 2011 |
| Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test SD Lawn, P Mwaba, M Bates, A Piatek, H Alexander, BJ Marais, ... The Lancet infectious diseases 13 (4), 349-361, 2013 | 612 | 2013 |
| Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial G Theron, L Zijenah, D Chanda, P Clowes, A Rachow, M Lesosky, W Bara, ... The Lancet 383 (9915), 424-435, 2014 | 551 | 2014 |
| Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000 S Osmanov, C Pattou, N Walker, B Schwardländer, J Esparza JAIDS Journal of Acquired Immune Deficiency Syndromes 29 (2), 184-190, 2002 | 504 | 2002 |
| Operational feasibility of using loop-mediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries CC Boehme, P Nabeta, G Henostroza, R Raqib, Z Rahim, M Gerhardt, ... Journal of clinical microbiology 45 (6), 1936-1940, 2007 | 459 | 2007 |
| New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects AI Zumla, SH Gillespie, M Hoelscher, PPJ Philips, ST Cole, I Abubakar, ... The Lancet infectious diseases 14 (4), 327-340, 2014 | 422 | 2014 |
| Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting G Theron, J Peter, R van Zyl-Smit, H Mishra, E Streicher, S Murray, ... American journal of respiratory and critical care medicine 184 (1), 132-140, 2011 | 406 | 2011 |
| Virological assessment of hospitalized cases of coronavirus disease 2019 KZ Ehmann, C Drosten, C Wendtner, M Zange, P Vollmar, ... Nature 581, 465-469, 2020 | 400 | 2020 |
| High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial MJ Boeree, N Heinrich, R Aarnoutse, AH Diacon, R Dawson, S Rehal, ... The Lancet infectious diseases 17 (1), 39-49, 2017 | 382 | 2017 |
| Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages D Stucki, D Brites, L Jeljeli, M Coscolla, Q Liu, A Trauner, L Fenner, ... Nature genetics 48 (12), 1535-1543, 2016 | 371 | 2016 |
| Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts BJ Marais, K Lönnroth, SD Lawn, GB Migliori, P Mwaba, P Glaziou, ... The Lancet infectious diseases 13 (5), 436-448, 2013 | 371 | 2013 |
| Drug-resistant tuberculosis: time for visionary political leadership I Abubakar, M Zignol, D Falzon, M Raviglione, L Ditiu, S Masham, I Adetifa, ... The Lancet infectious diseases 13 (6), 529-539, 2013 | 366 | 2013 |
| A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis MJ Boeree, AH Diacon, R Dawson, K Narunsky, J Du Bois, A Venter, ... American journal of respiratory and critical care medicine 191 (9), 1058-1065, 2015 | 360 | 2015 |
| Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis G Riedner, M Rusizoka, J Todd, L Maboko, M Hoelscher, D Mmbando, ... New England Journal of Medicine 353 (12), 1236-1244, 2005 | 350 | 2005 |
| Prospective study of acute HIV-1 infection in adults in East Africa and Thailand ML Robb, LA Eller, H Kibuuka, K Rono, L Maganga, S Nitayaphan, ... New England Journal of Medicine 374 (22), 2120-2130, 2016 | 323 | 2016 |
| Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers RS Wallis, M Maeurer, P Mwaba, J Chakaya, R Rustomjee, GB Migliori, ... The Lancet infectious diseases 16 (4), e34-e46, 2016 | 308 | 2016 |
| Host-directed therapies for infectious diseases: current status, recent progress, and future prospects A Zumla, M Rao, RS Wallis, SHE Kaufmann, R Rustomjee, P Mwaba, ... The Lancet Infectious Diseases 16 (4), e47-e63, 2016 | 303 | 2016 |
| Preferential infection and depletion of Mycobacterium tuberculosis–specific CD4 T cells after HIV-1 infection C Geldmacher, N Ngwenyama, A Schuetz, C Petrovas, K Reither, ... Journal of Experimental Medicine 207 (13), 2869-2881, 2010 | 296 | 2010 |
Andrea RachowDivision of Infectious Diseases & Tropical Medicine at LMU Munich在 lrz.uni-muenchen.de 的电子邮件经过验证
